Neuromuscular

November 30, 2020

Rozanolixizumab was associated with reductions in anti-acetylcholine receptor autoantibodies and was well tolerated across 2 dose levels with no new safety findings.

November 30, 2020

Here's what is coming soon to NeurologyLive.

November 29, 2020

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

November 27, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

November 25, 2020

Seelos Therapeutics will soon enroll patients in its phase 2b/3 trial of SLS-005 in amyotrophic lateral sclerosis.

November 25, 2020

The professor of neurology at the NYU Langone Grossman School of Medicine detailed the ways the COVID-19 pandemic impacted mental health of frontline clinicians.

November 25, 2020

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

November 23, 2020

Evidence from 2 clinical trials were the basis of the biologics license application, with an FDA decision expected to be made by May 18, 2021.

November 23, 2020

Here's what is coming soon to NeurologyLive.

November 20, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 20, 2020.

November 20, 2020

After the 12-month open-label period, those treated with patisiran from the phase 3 APOLLO and phase 2 open-label parent studies maintained their improvements on the modified Neuropathy Impairment Score +7.

November 20, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.